Authors
Latest:
Dr. Nabors on Evolving Treatment Options for Brain MetastasesLouis B. Nabors, MD, of University of Alabama, Birmingham Comprehensive Cancer Center, discusses the evolving treatment landscape for patients with brain metastases.
Latest:
Dr. Weiner on the Criteria Required to Become an NCI-Designated Cancer CenterLouis M. Weiner, MD, director of the Georgetown Lombardi Comprehensive Cancer Center, discusses the criteria required to become an NCI-designated cancer center.
Latest:
Combined Radiation Therapy and Checkpoint Inhibition in Lymphoma: A Case Report and Brief ReviewThe emergence of immune checkpoint inhibitors as an effective treatment strategy is a result of increased understanding of the elaborate relationship between tumor cells, their microenvironment and the host immune response.
Latest:
Dr. Anthony on the Pathology of Neuroendocrine TumorsLowell Anthony, MD, chief, Division of Medical Oncology, University of Kentucky Markey Cancer Center, discusses the various subtleties in defining the pathology of neuroendocrine tumors.
Latest:
Dr. Anthony on Treatment Benefit With Telotristat Epitrate in Patients With Carcinoid SyndromeLowell B. Anthony, MD, professor of Medicine, University of Kentucky, discusses patient exit interviews from the phase III placebo-controlled TELESTAR trial, which evaluated telotristate epitrate in patients with inadequately controlled carcinoid syndrome.
Latest:
Dr. Anthony on Spartalizumab in NETsLowell B. Anthony, MD, FACP, chief, Division of Medical Oncology, University of Kentucky Markey Cancer Center, discusses preliminary research with spartalizumab (PDR001) in neuroendocrine tumors (NETs).
Latest:
Dr. Hart on Personalized Treatment Approach for Patients With HER2+ Breast CancerLowell L. Hart, MD, discusses personalized treatment approaches for patients with HER2-positive breast cancer.
Latest:
Dr. Hart on Detecting and Treating Interstitial Lung Disease in HER2+ Breast CancerLowell L. Hart, MD, FACP, discusses detection and treatment of interstitial lung disease for patients with HER2-positive breast cancer who received fam-trastuzumab deruxtecan-nxki.
Latest:
Dr Costa on the Clinical Implications of the MASTER Trial in Multiple MyelomaLuciano J. Costa, MD, PhD, discusses clinical implications derived from a final analysis of the phase 2 MASTER trial, which evaluated quadruplet induction therapy in multiple myeloma.
Latest:
Dr. Mutti on Current Role of Immunotherapy for MesotheliomaLuciano Mutti, MD, professor of Cancer Research, University of Salford Manchester, discusses the current role of immunotherapy for patients with mesothelioma.
Latest:
Dr. Crinò on Crizotinib in ALK-Positive NSCLCLucio Crinò, MD, discusses the results of the PROFILE 1007 trial that compared crizotinib with standard chemotherapy as second-line therapy for advanced ALK+ non-small cell lung cancer
Latest:
CMS Should Broaden Coverage for Germline Mutation TestingSometimes referred to as massively parallel sequencing, next-generation sequencing evaluates millions of DNA sequences simultaneously, representing a true revolution compared with traditional, labor-intensive methods in which far less DNA could be sequenced at once.
Latest:
Dr. Luis A. Diaz, Jr. on Pembrolizumab For MMR-Deficient Colorectal CancerLuis A. Diaz, Jr. MD, associate professor of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, discusses the efficacy of PD-1 inhibitor pembrolizumab (Keytruda) in heavily pretreated colorectal cancer patients with mismatch repair (MMR).
Latest:
Dr. Diaz on Response Rates for MSI-H and NTRK Fusions in GI CancerLuis A. Diaz, MD, head of the division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center, discusses the responses seen with microsatellite-instability high (MSI-H) and NTRK fusions in patients with gastrointestinal cancer.
Latest:
Genetic Analysis of Remote Population May Advance Breast Cancer Prevention and TreatmentUsing blood samples collected from the Andean villagers, the laboratory at the UC Davis Genome Center uses a variety of high-throughput genetic analysis techniques to screen for genetic differences.
Latest:
Dr Raez on the FDA Approval of Repotrectinib in NTRK+ Solid TumorsLuis E. Raez, MD, FACP, FCCP, discusses the significance of the FDA approval of repotrectinib in solid tumors harboring an NTRK gene fusion.
Latest:
Dr Paz-Ares on the Challenges of NGS in NSCLCLuis G. Paz-Ares, MD, PhD, discusses the importance of next-generation sequencing and highlights current challenges with NGS for patients with non–small cell lung cancer.
Latest:
Dr Paz-Ares on Tusamitamab Ravtansine in CEACAM5-Positive NSCLCLuis Paz-Ares, MD, PhD, discusses efficacy and safety findings from the phase 2 CARMEN-LC05 trial of tusamitamab ravtansine in patients with nonsquamous non–small cell lung cancer with CEACAM5 expression.
Latest:
Dr. Blanco on the Role of Pathology in Treatment of Breast CancerLuis Z. Blanco Jr., MD, assistant professor of Pathology, Northwestern University, discusses the role a pathologist plays in the treatment of a patient with breast cancer during a presentation at the Lynn Sage Breast Cancer Symposium.
Latest:
Dr. Iruela-Arispe on the Dr. Paul Janssen Award SymposiumDr. Luisa Iruela-Arispe from University of California, Los Angeles on the Dr. Paul Janssen Award Symposium
Latest:
Next Steps for Wnt Research in Colorectal CancerLuke Dow, PhD, discusses the next steps for researching the Wnt pathway in colorectal cancer.
Latest:
Dr. Nordquist on Matching Patients to Clinical TrialsLuke Nordquist, MD, FACP, discusses matching patients with clinical trials in oncology.
Latest:
Dr. Luke Nordquist on Who Should Receive Radium-223Luke Nordquist, MD, a urologic medical oncologist and CEO of the Urology Cancer Center and GU Research Network, discusses which patients may benefit from radium-223, those who should not receive the drug, and combinations that are being considered.
Latest:
Dr. Luke Nordquist on Radium-223 RetreatmentLuke Nordquist, MD, FACP, a urologic medical oncologist and CEO of the Urology Cancer Center and GU Research Network, discusses a multicenter, prospective study of radium-223 retreatment in metastatic castration-resistant prostate cancer (mCRPC).
Latest:
Putting the Genome to Work in Breast CancerAn interview with Elaine R. Mardis, PhD, discussing the clinical applications of genomic research on the near horizon that will enable more personalized therapy for patients at earlier stages of breast cancer.
Latest:
Dr. Willmott on Expanding Genomic Testing in Ovarian CancerLyndsay Willmott, MD, discusses the expanding role for genomic testing in ovarian cancer.
